Information by Drug Class
FDA provides consumers and industry with safety, regulatory and availability information for various drugs by drug class. From A to…
Frequently Asked Questions About Therapeutic Biological Products
Frequently Asked Questions About Therapeutic Biological Products
Drug Safety Oversight Board Meetings – Public Summaries
This page provides summaries of past DSB Meetings. Each summary include DSCs posted since the last meeting, topics presented and…
Products Approved for Anthrax
Discover FDA-approved products for anthrax preparedness and response. Get essential information on vaccines, treatments, and preventive measures to protect public…
FDA Roundup: March 14, 2025
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.
FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan)
Stay informed on FDA updates and press announcements about recalls involving angiotensin II receptor blockers (ARBs) like valsartan and losartan.…
Novel Drug Approvals for 2022
Innovative drugs often mean new treatment options for patients and advances in health care for the American public.
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to…
Science & Research
In collaboration with industry and the public, FDA creates an annual list of regulatory science initiatives on generic drugs.
Generic Drug Development
News and Announcements updated